BEYOND BODY MASS INDEX: UNCOVERING “HIDDEN” CARDIOMETABOLIC RISK IN NORMAL-WEIGHT TYPE 2 DIABETES PATIENTS USING WHTR AND AIP TRAJECTORIES
Keywords:
Cardiometabolic continuum; Visceral adiposity; Residual cardiovascular risk; Atherogenic Index of Plasma; Waist-to-height ratio; Normal-weight obesity; Type 2 diabetes.Abstract
Doctors routinely rely on Body Mass Index (BMI) to assess weight-related health, but it often misses hidden cardiovascular dangers in patients with type 2 diabetes (T2DM) who look lean or have a normal weight. This review examines how visceral fat accumulation and silent changes in lipid quality drive vascular damage in these non-obese individuals, and how we can catch these risks early. Analyzing recent data from high-impact cohort studies, clinical trials, and meta-analyses published between 2021 and 2026, we evaluate two practical, non-traditional tools: the waist-to-height ratio (WHtR) and the atherogenic index of plasma (AIP). The gathered evidence shows that WHtR is a highly reliable marker for hormonally active visceral fat, flagging elevated cardiovascular mortality risks even when a patient's BMI appears perfectly healthy. Meanwhile, AIP acts as a sensitive window into blood chemistry, detecting dangerous small, dense LDL particles—the driving force behind "residual" vascular risk that standard cholesterol tests often miss. When used together, WHtR and AIP track both the physical presence of belly fat and its toxic metabolic output, making it much easier to spot subclinical blood vessel damage before severe complications set in. Ultimately, moving away from a strict reliance on BMI toward a combined WHtR/AIP approach offers a simple, affordable, and non-invasive strategy. This dual-predictor model eliminates dangerous clinical blind spots, helping primary care physicians provide timely, life-saving cardiovascular prevention for normal-weight patients living with type 2 diabetes.
References
International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels: International Diabetes Federation; 2021.
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227–337. doi:10.1093/eurheartj/ehab484
Jayedi A, Soltani S, Zargar MS, Khan TA, Shab-Bidar S. Central adiposity and risk of all cause mortality: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ. 2020 Sep 23;370:m3324. doi:10.1136/bmj.m3324
Tomlinson DJ, Erskine RM, Morse CI, Winwood K, Onambélé-Pearson GL. The impact of obesity on skeletal muscle strength, muscle composition and technical modality: a systematic review and meta-analysis. Obes Rev. 2016 Jan;17(1):33–50. doi:10.1111/obr.12328
Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite LDL-C-lowering therapy: Target small dense LDL in the cardiometabolic continuum. Current Atherosclerosis Reports. 2012;14(2):107–14.
Lo K, Wong M, Khalechelvam P, Tam W. Waist-to-height ratio, waist circumference and body mass index as indices of cardiometabolic risk among children and adolescents. Childhood Obesity. 2016;12(4):256–65.
Ke P, Shen J, Ren X, Zhai X, Chang G, Feng J, et al. Comparison of several anthropometric indices as predictors of cardiovascular diseases among patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2022;14(1):92. doi:10.1186/s13098-022-00862-2
Ashwell M, Gibson S. Waist-to-height ratio as an indicator of early health risk: simpler and more predictive than BMI. BMJ. 2016;353:i1951.
Ma L, Zhang S, Wang J. Evaluation of waist-to-height ratio in diagnosing metabolic syndrome in adult populations with type 2 diabetes. J Diabetes Complications. 2022;36(5):108172.
Park Y, Kim J, Choi W. Waist-to-height ratio trajectories and long-term cardiovascular mortality in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2026;14(2):112–21.
Liao H, Chen X, Yang W. Anthropometric indicators and prevalent cardiovascular diseases in non-obese diabetic populations: A cross-sectional analysis. Cardiovascular Diabetology. 2025;24(1):45.
Zhou M, Zhu L, Cui X, Feng L, Bao Y. Atherogenic Index of Plasma Is a Sensitive Predictor of Coronary Artery Disease in Patients with Type 2 Diabetes Mellitus. Biomedical Research International. 2021;2021:6643210. doi:10.1155/2021/6643210
Kim J, Cho K, Park H. Atherogenic Index of Plasma and the Risk of Ischemic Stroke and Myocardial Infarction: A Nationwide Cohort Study. Arterioscler Thromb Vasc Biol. 2022;42(8):1021–30.
Qin Z, Zhou K, Li Y, Bhatkar S, Kou J, Tang J, et al. The atherogenic index of plasma plays an important role in predicting long-term outcomes of type 2 diabetic patients undergoing percutaneous coronary intervention. Cardiovasc Diabetol. 2020 Nov 23;19(1):198. doi:10.1186/s12933-020-01174-x
Wen J, Yang M, Long-term 10-year trajectories of atherogenic index of plasma and development of macrovascular complications in type 2 diabetes. Diabetes Care. 2025;48(3):562–71.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo